SBI Securities’s Elicio Therapeutics ELTX Stock Holding History

SBI Securities’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$716	Buy	183 +101	+123%	+$1.01K	﹤0.01%	2919
2026 Q1	$877	Hold	82	–	–	﹤0.01%	2705
2025 Q4	$653	Hold	82	–	–	﹤0.01%	2781
2025 Q3	$897	Sell	82 -1	-1%	-$10	﹤0.01%	2739
2025 Q2	$641	Hold	83	–	–	﹤0.01%	2860
2025 Q1	$511	Hold	83	–	–	﹤0.01%	2867
2024 Q4	$423	Buy	+83	New	+$409	﹤0.01%	2954

Other funds holding ELTX

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

MFA

Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return

MLL

Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SBI Securities's ELTX Position: Q2 2026 in Review

SBI Securities increased its Elicio Therapeutics (ELTX) stake by 123% in Q2 2026, buying an estimated $1.01K and bringing the position to 183 shares worth $716. The position accounts for ﹤0.01% of the portfolio, ranked #2919.

SBI Securities first reported a position in ELTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $897 in Q3 2025. 5 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

SBI Securities held 183 shares of Elicio Therapeutics worth $716 as of Q2 2026.
SBI Securities bought 101 Elicio Therapeutics shares in Q2 2026, an estimated $1.01K.
Elicio Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2919 holding.
SBI Securities first reported a position in Elicio Therapeutics in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Elicio Therapeutics position peaked at $897 in Q3 2025.
5 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.